The tornado was also the costliest tornado in history at the time (unadjusted for inflation), but in the years since has been surpassed by several others if population changes over time are not considered. When costs are normalized for wealth and inflation, it ranks third today.The deadliest tornado in world history was the Daultipur-Salturia Tornado in Bangladesh on April 26, 1989, which killed approximately 1,300 people.Bangladesh has had at least 19 tornadoes in its history that killed more than 100 people, almost half of the total in the rest of the world.One of the most extensive tornado outbreaks on record was the 1974 Super Outbreak, which affected a large area of the central United States and extreme southern Ontario on April 3 and 4, 1974. The outbreak featured 148 tornadoes in 18 hours, many of which were violent; six were of F5 intensity, and twenty-four peaked at F4 strength. Sixteen tornadoes were on the ground at the same time during its peak. More than 300 people, possibly as many as 330, were killed.While direct measurement of the most violent tornado wind speeds is nearly impossible, since conventional anemometers would be destroyed by the intense winds and flying debris, some tornadoes have been scanned by mobile Doppler radar units, which can provide a good estimate of the tornados winds.
Significant correlation between treatment-associated molecular changes and PASI improvement was observed in the risankizumab treated patients.The efficacy, safety and tolerability was further investigated in a phase III program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results of these trials confirmed the efficacy and tolerability of risankizumab. History
Risankizumab was approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe plaque psoriasis in April 2019.The FDA approved risankizumab based on evidence primarily from five clinical trials (Trial 1/NCT0202684370, Trial 2/NCT02684357, Trial 3/NCT02672852, Trial 4/ NCT02694523 and Trial 5/NCT02054481) of 1606 patients with moderate to severe plaque psoriasis. The trials were conducted in Asia, Canada, Europe, Mexico, South America, and the United States. References
External links
"Risankizumab". Drug Information Portal. U.S. National Library of Medicine.